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Background: Extended spectrum beta-lactamase producing bacteria (ESBL) are common causes of neonatal sepsis
worldwide. Neonatal sepsis due to ESBL is associated with increased morbidity and mortality at Bugando Medical
Centre (BMC). Due to limited information on the sources of these ESBL strains at BMC, this study was conducted to
evaluate the existence, magnitude and transmission of ESBL from post-delivery women to neonates at BMC,
Mwanza-Tanzania.
Results: A cross-sectional study was conducted at obstetrics and neonatal wards from May to July 2013, involving
post-delivery women and their neonates. Rectal swabs were collected and processed to identify the ESBL strains
and their antimicrobial susceptibility patterns. Patients’ data were obtained using a standardized data collection tool.
We enrolled 113 women and 126 neonates with mean age of 26.5 ± 5.5 years and median gestation age [IQR] of 39
[35–40] weeks respectively. The prevalence of ESBL carriage among women and neonates were 15% (17/113) and
25.4% (32/126) respectively. The acquisition of ESBL isolates among neonates on day 1, day 3 and day 7 were 60.0%
(21/35), 25.7% (9/35) and 14.3% (5/35) respectively. There was no phenotypic similarity between ESBL strains from
women and their respective neonates, suggesting other sources of transmission. Neonates given antibiotics were
more likely to carry ESBL than those not given [100% (32/32) versus 86% (81/94), p = 0.018].
Conclusion: The carriage rate of ESBL strains among post-delivery women and neonates at BMC is high. Our
findings suggest that neonates acquire these strains from sources other than post-delivery women and more than
half acquire them on the first day of life. More studies are recommended to further explore the sources of ESBL
strains among neonates.
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The escalating burden of multidrug resistant (MDR)
gram negative bacteria of the family Enterobacteriaceae
is currently one of the most challenging situations both
in developed and developing countries [1-4]. The ex-
posure of these bacteria notably, Escherichia coli and
Klebsiella pneumoniae to antibiotics especially in the* Correspondence: senijj80@gmail.com
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unless otherwise stated.hospital environment has induced dynamic and continu-
ous mutation leading to production extended spectrum
beta lactamase (ESBL) which confer resistance to first,
second, third and fourth generation cephalosporins as
well as aztreonam [5-7]. These ESBL strains in turn
have spread not only in the hospital environment but
also to the community settings with significant regional
variations [4,6,8,9].
Although shown in few studies, gastrointestinal carriage
of ESBL strains can be a predictor of subsequent infection
[10-12]. The prevalence of ESBL carriage has been shownLtd. This is an Open Access article distributed under the terms of the Creative
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nant women colonized by ESBL in the gastrointestinal
tract have a potential to subsequently transmit these
strains to their neonates (during and after delivery), to
other hospitalized patients and to health workers [17,18].
Few studies have addressed the magnitude of ESBL as-
sociated infections with undue complications and deaths
in Tanzania [3,9,19-21] however information showing
the ESBL carriage among post-delivery women and their
neonates remain to be explored. Thus, this study aimed
at evaluating the existence, magnitude and transmission
of ESBL strains from post-delivery women to their neo-
nates during or after delivery so as to specifically guide
infection prevention and control at Bugando Medical
Center (BMC) where ESBL associated infections have
been shown to be an independent predictor of deaths
among neonates [3].
Methods
Study design and sampling procedures
This was a cross sectional hospital based study con-
ducted from May to July 2013 in the obstetrics wards,
neonatal ICU and neonatal wards at BMC. Post-delivery
women who delivered at BMC within 24 hours and who
consented to participate in the study were serially re-
cruited and their respective neonates. The sample size
of 113 post-delivery women was estimated using Kish
Leslie (1965) formula and using a previous prevalence
of 8% [14].
Data and clinical sample collection
Every post-delivery woman was informed about details
regarding the aims of the study. A standardized data
collection tool and patients’ files were used to collect
demographic and clinical data among consented women
and their respective neonates.
Then, after a thorough explanation, using sterile cotton
swab in Amies transport medium (Biolab, HUNGARY)
rectal swabs were collected from women within 24 hours
after delivery. To assess acquisition of ESBL strains in neo-
nates, the rectal swabs were collected on day 1, day 3 and
day 7 post-delivery. Rectal swab specimens were delivered
to the Laboratory within two hours after collection.
Laboratory procedures
The rectal swab samples were plated onto MacConkey
agar (OXOID, Basingstoke, UK) supplemented with cefo-
taxime 2 mg/L for preliminary screening of ESBL bacterial
isolates and then plates were incubated at 35-37°C for
18–24 hours. All gram negative bacteria were identified
using phenotypic characteristics such as lactose fermenta-
tion reaction on Mac Conkey agar, Urease, Citrate, Sulphur
indole motility (SIM) and Triple sugar iron (TSI) tests
as previously described [22].Susceptibility testing was done using disc diffusion
method based on the Clinical Laboratory Standard In-
stitute (CLSI) guideline [23]. The antibiotic discs tested
were ampicillin (10 μg), amoxicillin/clavulanate (20/10 μg),
ciprofloxacin (5 μg), tetracycline (30 μg), gentamicin
(10 μg), sulfamethoxazole/trimethoprim (1.25/23.75 μg),
ceftriaxone (30 μg), ceftazidime (30 μg) and imipenem
(10 μg) (OXOID, Basingstoke, UK). The phenotypic
confirmation of ESBL isolates was done using disc ap-
proximation method i.e. ceftazidime (30 μg) and cefo-
taxime (30 μg) discs were placed equidistant from the
amoxicillin/clavunate (20/10 μg) disc, followed by over-
night incubation at 37°C for 18–24 hrs. Enhanced zone
of inhibition towards amoxicillin/clavulanate disc was
considered as positive result for ESBL production whereas
interpretation of susceptibility patterns on other anti-
microbial disks was done using guidelines laid down in
the CLSI, which provides break points corresponding to
zone of inhibition diameter [9,23].
Quality control
Standard laboratory procedures were strictly adhered to so
as to avoid contamination. Escherichia coli ATCC 25922
and Escherichia coli ATCC 35218 were used as negative
and positive ESBL controls respectively.
Data management and analysis
The demographic, clinical and laboratory data were en-
tered into Microsoft excel and then exported to the STATA
version 11.0 software for analysis according to the objec-
tives of the study. Results were presented into percentages/
proportions for categorical variables whereas continuous
variables were described as mean (±standard deviation).
The difference in distribution of predictor variable was
considered significant if p-value was less than 0.05.
Study clearance and ethical consideration
The study was approved by CUHAS/BMC Ethical Review
Board, and written informed consent was obtained from
every post-delivery woman (who also provided consent for
her neonate) before collection of demographic, clinical
data and rectal swab specimens.
Results
A total of 113 post-delivery women and 126 neonates with
mean age of 26.5 ± 5.5 years and median gestation age
[IQR] of 39 [35–40] weeks respectively were recruited.
The prevalence of ESBL carriage among post-delivery
women and neonates were 15% (17/113) and 25.4% (32/
126) respectively. The cumulative number of ESBL bacter-
ial isolates among post-delivery women and neonates were
found to be 20 and 35 respectively throughout the study
(three post-delivery women and neonates had dual ESBL
carriage). The most predominant ESBL isolates among
Figure 1 The proportion of ESBL bacterial isolates’ carriage among post-delivery women and neonates at BMC.
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followed by Enterobacter spp (20%, 4/20) whereas the pre-
dominant species in neonates were Klebsiella pneumoniae
(77.1%, 27/35) followed by Escherichia coli (14.3%, 5/35)
(Figure 1).
The acquisition of ESBL isolates among neonates on
day 1, day 3 and day 7 were 60.0% (21/35), 25.7% (9/35)
and 14.3% (5/35) respectively. Furthermore, there was noTable 1 Association between ESBL carriage among post-deliv
Variable Non ES
Mean age ± SDǂ
Mode of delivery C/S*
SVD**
Admission in the past 30 days No
Yes
Admission in the past 3 months No
Yes
Previous use of antibiotics in the past 30 days No
Yes
Previous use of antibiotics in the past 3 months No
Yes
Antibiotics use in the current admission No
Yes
Presence of catheter No
Yes




ǂStandard deviation; *Caesarean section; **Spontaneous vaginal delivery.phenotypic similarity between ESBL strains from post-
delivery women and their respective neonates.
There was no statistical significant association between
ESBL-carriage among post-delivery women and variables
such as age, mode of delivery, history of antibiotic use in
the past or current admission, the presence of i/v line,
urinary catheter insitu as well as HIV seropositivity. Ne-
onates given antibiotics were more likely to carry ESBLery women with variables
BL carrier, n (%) ESBL carrier, n (%) p-value
N = 96 N = 17
27.1 ± 5.5 years 23.4 ± 3.6 years 0.084
36 (37.5) 8 (47.1) 0.456
60 (62.5) 9 (52.9)
96 (100) 17 (100) -
0 (0.0) 0 (0.0)
83 (86.5) 13 (76.5) 0.288
13 (13.5) 4 (23.5)
67 (69.8) 9 (52.9) 0.172
49 (30.2) 8 (47.1)
54 (56.3) 7 (41.2) 0.250
42 (43.7) 10 (58.8)
57 (59.4) 9 (52.9) 0.620
39 (40.6) 8 (47.1)
59 (61.5) 10 (58.8) 0.837
37 (38.5) 7 (41.2)
54 (56.3) 10 (58.8) 0.844
42 (43.7) 7 (41.2)
84 (87.5) 16 (94.1) 0.431
12 (12.5) 1 (5.9)
Table 2 Association between ESBL carriage among neonates with variables
Variable Non ESBL carrier, n ESBL carrier, n p-value
N = 94 N = 32
Median gestational (IQR)ǂ 39 (35–40) 39 (35–40) 0.710
Median birth weight (kg) 2.6 (1.9-3) 2.9 (1.7-3.4) 0.365
Sex Female 44 (46.8%) 17 (53.1%) 0.537
Male 50 (53.2%) 15 (46.9%)
Mode of Delivery C/S* 35 (37.2%) 12 (37.5%) 0.979
SVD** 59 (62.8%) 20 (62.5%)
Ward NICU× 19 (20.2%) 8 (25.0%) 0.569
C2NU×× 75 (79.8%) 24 (75.0%)
Antibiotic Use No 13 (13.8%) 0 (0.0%) 0.018
Yes 81 (86.2%) 32 (100.0%)
Outcome Discharged 85 (90.4%) 28 (87.5%) 0.638
Died 9 (9.6%) 4 (12.5%)
ǂInterquantile range; *Caesarian section; **Spontaneous vagina delivery; ×Neonatal intensive care unit; ××Ward C2 neonatal unit.
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p = 0.018]. The mortality rates among neonates carrying
ESBL was relatively higher as opposed to non-carriers
though the difference was not statistically significant
(12.5%, 5/32 versus 9.6%, 9/94 respectively; p-value =
0.638) (Tables 1 & 2).
The ESBL bacterial isolates in this study showed bor-
derline resistance to ciprofloxacin among post-delivery
women (55.0%, 11/20) and neonates (34.3%, 13/35). All
ESBL strains were sensitive to imipenem (Table 3).
Discussion
The prevalence of ESBL carriage among women shown
in this study (15%) is relatively close to 10% to 12.7%
found in some Asian and African countries [13,15,16]
but lower than 3% and 3.2% in Sweden and USA respect-
ively [11,24]. The lower rates in ESBL carriage in devel-
oped countries as opposed to developing countries may be
attributable to different policies in antimicrobial use and
infection control in the respective settings. The present
study and a similar one in Madagascar found the rates of
ESBL carriage in children to be 15% and 22.1% respect-
ively, with acquisition increasing progressively in the
course of hospitalization [25]. This emphasizes the needTable 3 Antimicrobial resistance patterns among ESBL
isolates from post-delivery women and neonates
Antimicrobial
agents
Post-delivery women, n (%) Neonates, n (%)
N = 20 N = 35
Co-trimoxazole 20 (100.0) 25 (71.4)
Tetracycline 14 (70.0) 17 (48.6)
Gentamicin 15 (75.0) 32 (91.4)
Ciprofloxacin 11 (55.0) 12 (34.3)
Imipenem 0 (0.0) 0 (0.0)to protect this vulnerable population of children against
the MDR strains in the hospital settings. The predomin-
ance of Escherichia coli and Klebsiella pneumonia produ-
cing ESBL strains in this study is also similar to findings in
some other studies across the world showing their prepon-
derance in gastrointestinal tract colonization and their
evolutionary potential into MDR strains [12,15,25,26].
It is well known that gastrointestinal carriage of ESBL
strains among pregnant women can be a potential source
of transmitting these resistant strains to their newborns
[17,18] but contrary to this, there was no phenotypic simi-
larity between ESBL strains from women and their re-
spective neonates. This suggests that effective control of
transmission of ESBL strains at BMC should go beyond
mothers and that other possible sources should be further
scrutinized so as to curb the growing burden of antimicro-
bial resistance in Tanzania [3,20] and other countries with
similar problem [4,7].
As shown in some other studies [25-29], previous use
of antibiotics among neonates has also been shown to be
associated with ESBL carriage in the present study. The
possible reason of high neonatal ESBL carriage in our
setting may be due to antimicrobial selective pressure
conferred by the empirical use of ampiclox and cefotax-
ime. Therefore, as shown from other settings [11], neo-
natal screening for ESBL strains and adherence to the
rational antimicrobial use policy should be an enduring
exercise at BMC. Other predictive factors such as older
age, prolonged hospitalization, vaginal delivery, low birth
weight and prematurity though shown in other studies
[14,25,26,30] were not found to be statistically associated
with ESBL carriage in the present study.
The MDR nature of the ESBL isolates in the present
study is worrisome as these post-delivery women and
their neonates may be the potential sources of these
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sity be among the target groups in infection prevention
and control activities at BMC. The present study has
shown excellent activity of carbapenems and borderline
activity of ciprofloxacin against ESBL strains, the find-
ings which are similar to other studies [8,25].
Conclusion
The carriage rates of ESBL strains among neonates and
their mothers at BMC are high. Our findings suggest
that neonates acquire these strains from sources other
than post-delivery women and more than half acquire
them on the first day of life. These two groups should be
among the target groups for ESBL screening at BMC so
as to prevent ESBL spread in the hospital environment.
In the light of these findings, more studies are recom-
mended to further explore the sources of the ESBL strains
among neonates.
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